Re‐re‐biopsy? How much tumor is enough in the era of precision oncology?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Re‐re‐biopsy? How much tumor is enough in the era of precision oncology?
Authors
Keywords
-
Journal
Asia Pacific Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-03
DOI
10.1111/ajco.14030
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
- (2022) Laura Bonanno et al. BRITISH JOURNAL OF CANCER
- Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
- (2022) Soon Hin How et al. Cancer Management and Research
- OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
- (2021) K. Nakagawa et al. Journal of Thoracic Oncology
- LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
- (2021) Yingqiang Liu et al. CANCER SCIENCE
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
- (2019) Juan Zhou et al. Thoracic Cancer
- 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
- (2019) Y-L Wu et al. ANNALS OF ONCOLOGY
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health economic impact of liquid biopsies in cancer management
- (2018) Maarten J. IJzerman et al. Expert Review of Pharmacoeconomics & Outcomes Research
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
- (2018) Hanping Wang et al. OncoTargets and Therapy
- A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
- (2017) E-E Ke et al. Journal of Thoracic Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
- (2016) Yue-Lun Zhang et al. Oncotarget
- EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey
- (2015) Yasushi Yatabe et al. Journal of Thoracic Oncology
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
- (2015) Kenneth S. Thress et al. LUNG CANCER
- Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
- (2014) Paul A. VanderLaan et al. LUNG CANCER
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation